News

Obesity drug boom has a new pecking order
The pecking order of the obesity drug market is shifting. Eli Lilly , the $815 billion maker of blockbuster weight-loss drugs ...
Zacks Investment Research on MSN20h
Novo Nordisk Plunges 17% in a Month: Buy, Sell or Hold the Stock?
Novo Nordisk NVO shares have lost 16.7%, attributable to both sector-specific developments and broader macroeconomic ...
News-Medical.Net on MSN10h
What’s behind Gen Z’s skepticism about Ozempic and Wegovy
A U.S. study of over 500 youth aged 14–24 found high awareness but widespread hesitation about using semaglutide for weight ...
Healio6h
Semaglutide adverse events named in nearly 25,000 ED visits in 2 years since approval
An estimated 24,499 people visited the ED for adverse events related to semaglutide in the 2 years after its approval for ...
Ozempic copies restricted after US judge deni
April 24 - A U.S. judge on Thursday rejected a bid by compounding pharmacies to keep making copies of Novo Nordisk's popular diabetes and weight-loss drugs Ozempic and Wegovy while a legal challenge ...
The Best Stock to Buy With Less Than $60 in the Market Sell-Off
One such example is Novo Nordisk (NYSE: NVO), the Denmark-based pharmaceutical leader whose shares are exchanging hands for ...
Business Today14h
Nifty 50 Equal Weight
What was Nifty 50 Equal Weight share price previously? Nifty 50 Equal Weight share price was up by 1.29% from the previous closing price of 29,789.65 What has been 52-week high of Nifty 50 Equal ...